Lynparza is approved in 64 countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, according to the data monitoring body for the phase 3 OlympiA trial.

Merck & Co.is ending a late-stage study of the combination of Keytruda and Lynparza in certain lung cancer patients due to an expected failure of the trial. The Rahway, N.J., drugmaker ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...

Recent FDA approvals include Rubraca, Lynparza, Akeega, and Talzenna, enhancing treatment options for BRCA-mutated prostate cancer. Approximately 25% of metastatic castration-resistant prostate cancer ...

Hardy says the potential to expand the use of Keytruda and Lynparza to a wider range of indications could also be a growth driver. CFRA has a "buy" rating and $135 price target for MRK stock ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Hardy is particularly impressed by Merck's cardiology and oncology portfolios and anticipates regulatory approval of expanded indications for Keytruda and Lynparza. He says Acceleron Pharma ...

Shares of Repare Therapeutics RPTX gained 8% on Monday after it announced dosing the first patient in an early-stage study evaluating the combination regimen of its Polθ ATPase inhibitor, RP-3467 ...

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...